Bristol-Myers Squibb Co.
) recently entered into a strategic alliance with privately-held
biopharmaceutical company Santaris Pharma A/S to discover and
develop medicines on a global basis using latter's proprietary
Locked Nucleic Acid (LNA) Drug Platform.
As per the terms of the agreement, Santaris is eligible for an
upfront payment of $10 million along with milestone payments of
$90 million. Additionally, Santaris will also receive royalties
on the worldwide sales of all medicines arising from the
Earlier in the month, Bristol-Myers entered into a
non-exclusive agreement with
) for the phase II development of once-daily all-oral treatment
regimens, which will combine Vertex Pharma's VX-135 and
Bristol-Myers' daclatasvir for the treatment of hepatitis C virus
Under the terms of the agreement, Vertex Pharma would conduct
two phase II studies with the combination. This includes an
initial study that will begin in the second quarter of 2013 in
treatment-naïve patients with genotype 1 HCV infection.
Subsequent to obtaining data from the study, Vertex Pharma
will commence another study, potentially in the second half of
the year, in treatment-naïve patients with genotype 1, 2 or 3 HCV
infection, including patients with cirrhosis.
Vertex will evaluate the safety, tolerability,
pharmacokinetics and viral cure rates (SVR4 and SVR12) of several
all-oral regimens of VX-135 plus daclatasvir dosed once daily in
We note that Bristol-Myers is looking to combat the generic
threat hanging over its key drugs through partnering deals and
acquisitions and introducing new products to augment its product
Bristol-Myers carries a Zacks Rank #3 (Hold).
Gilead Sciences Inc
) look well placed in the biopharma space. While UCB SA carries a
Zacks Rank #1 (Strong Buy), Gilead Sciences has a Zacks Rank #2
BRISTOL-MYERS (BMY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
VERTEX PHARM (VRTX): Free Stock Analysis
To read this article on Zacks.com click here.